Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

117.43
+0.02000.02%
Volume:5.95M
Turnover:706.28M
Market Cap:146.24B
PE:309.03
High:119.95
Open:117.00
Low:116.78
Close:117.41
Loading ...

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.
·
01 Mar

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Zacks
·
01 Mar

Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating

MT Newswires Live
·
01 Mar

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Zacks
·
28 Feb

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 Feb

Salesforce Stock Falls On Weak Revenue Outlook Amid Artificial Intelligence Push

Blockhead
·
27 Feb

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Zacks
·
26 Feb

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks
·
26 Feb

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Zacks
·
26 Feb

Top Stock Reports for Charles Schwab, Gilead Sciences & Medtronic

Zacks
·
26 Feb

Healthcare Stocks Should Be Hurting. How the Sector Became This Year's Top Performer. -- Barrons.com

Dow Jones
·
26 Feb

Morgan Stanley sees FDA approval of GILD's Lenacapavir

Investing.com
·
26 Feb

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

Zacks
·
26 Feb

Gilead Sciences Says Potential HIV Prophylaxis Applications Under Parallel Accelerated Review in EU

MT Newswires Live
·
24 Feb

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS
·
24 Feb

Gilead: Both Applications of Lenacapavir for Hiv Prevention Will Be Assessed in Parallel Under Accelerated Assessment Review Timeline

THOMSON REUTERS
·
24 Feb